Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:

“Breaking News in HER2+ Early Breast Cancer.

Today, topline results from the DESTINY-Breast11 Phase 3 trial were announced by AstraZeneca & Daiichi Sankyo:

Neoadjuvant Enhertu (trastuzumab deruxtecan) and THP demonstrated a statistically significant & clinically meaningful improvement in pathological complete response (pCR) compared to standard ddAC and THP in patients with high-risk, locally advanced HER2+ early breast cancer.

First Phase 3 trial of Enhertu in early breast cancer.
High-risk HER2+ eBC population.
Early event-free survival (EFS) trend favoured Enhertu.

This could be a paradigm-shifting moment in the neoadjuvant space!”

Amol Akhade: Topline Results From the DESTINY-Breast11 Phase 3 trial were announced by AstraZeneca and Daiichi Sankyo

More posts featuring Amol Akhade.